These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26002619)

  • 1. Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer.
    Loh KW; Michael M; Zalcberg JR; Jefford M
    Clin Colorectal Cancer; 2015 Sep; 14(3):192-7. PubMed ID: 26002619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
    Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer.
    Cartwright T; Chao C; Lee M; Lopatin M; Bentley T; Broder M; Chang E
    Curr Med Res Opin; 2014 Feb; 30(2):321-8. PubMed ID: 24127781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion?
    Sorscher S
    Curr Probl Cancer; 2018 Nov; 42(6):601-604. PubMed ID: 30119912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status on microsatellite instability, prognosis and adjuvant therapy in colon cancer: A nationwide survey of medical oncologists, colorectal surgeons and gastrointestinal pathologists.
    Toh JWT; Mahajan H; Chapuis P; Spring K
    Cancer Rep (Hoboken); 2021 Feb; 4(1):e1297. PubMed ID: 33030308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
    Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres.
    Grant M; Haydon A; Au L; Wilkins S; Oliva K; Segelov E; Antill Y; Carne P; Ranchod P; Polglase A; Farmer C; Chin M; Wale R; Simpson P; Bell S; Skinner S; McMurrick P; Shapiro J
    Int J Surg; 2018 Mar; 51():71-75. PubMed ID: 29367039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer.
    Shaib WL; Zakka KM; Jiang R; Yan M; Alese OB; Akce M; Wu C; Behera M; El-Rayes BF
    Cancer; 2020 Sep; 126(18):4136-4147. PubMed ID: 32697360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer.
    Baek DW; Kang BW; Lee SJ; Kim HJ; Park SY; Park JS; Choi GS; Baek JH; Kim JG
    In Vivo; 2019; 33(2):649-657. PubMed ID: 30804154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
    Sargent DJ; Marsoni S; Monges G; Thibodeau SN; Labianca R; Hamilton SR; French AJ; Kabat B; Foster NR; Torri V; Ribic C; Grothey A; Moore M; Zaniboni A; Seitz JF; Sinicrope F; Gallinger S
    J Clin Oncol; 2010 Jul; 28(20):3219-26. PubMed ID: 20498393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
    Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.
    Brenner B; Geva R; Rothney M; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Gluzman A; Purim O; Shacham-Shmueli E; Shulman K; Mishaeli M; Man S; Soussan-Gutman L; Tezcan H; Chao C; Shani A; Liebermann N
    Value Health; 2016 Jan; 19(1):82-7. PubMed ID: 26797240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.
    Sinicrope FA; Foster NR; Yoon HH; Smyrk TC; Kim GP; Allegra CJ; Yothers G; Nikcevich DA; Sargent DJ
    J Clin Oncol; 2012 Feb; 30(4):406-12. PubMed ID: 22203756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer.
    Sinicrope FA
    Nat Rev Clin Oncol; 2010 Mar; 7(3):174-7. PubMed ID: 20190798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
    Benson AB; Schrag D; Somerfield MR; Cohen AM; Figueredo AT; Flynn PJ; Krzyzanowska MK; Maroun J; McAllister P; Van Cutsem E; Brouwers M; Charette M; Haller DG
    J Clin Oncol; 2004 Aug; 22(16):3408-19. PubMed ID: 15199089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.
    Kim CA; Spratlin JL; Armstrong DE; Ghosh S; Mulder KE
    Clin Colorectal Cancer; 2014 Sep; 13(3):199-206. PubMed ID: 25088184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer.
    Krzyzanowska MK; Regan MM; Powell M; Earle CC; Weeks JC
    J Am Coll Surg; 2009 Feb; 208(2):202-9. PubMed ID: 19228531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.